Plus Therapeutics (PSTV) Total Non-Current Liabilities (2010 - 2025)

Plus Therapeutics (PSTV) reported Total Non-Current Liabilities of $7.3 million for Q2 2025, down 30.71% quarter-over-quarter from $10.6 million in Q1 2025.

Plus Therapeutics (PSTV) Total Non-Current Liabilities (2010 - 2025) Analysis & Trends

Plus Therapeutics (PSTV) has 11 years of Total Non-Current Liabilities data on file, last reported at $7.3 million in Q2 2025.

  • Total Non-Current Liabilities for Q2 2025 came in at $7.3 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $7.3 million (changed N/A YoY), and the FY2021 annual result was $11.1 million, up 22.91% from the prior year.
  • Total Non-Current Liabilities declined to $7.3 million in Q2 2025 per PSTV's latest filing, from $10.6 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $11.1 million in Q4 2021 and troughed at $7.3 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - 42,980.09
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - 11.03 Mn
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn 95.20 Mn
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -
7 Psyence Biomedical 238.34 Bn 238.33 Bn - 644,700.00
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn 5.87 Bn
9 Abivax 95.45 Bn 95.45 Bn - 64.76 Mn
10 Plus Therapeutics 34.26 Mn 19.15 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 7.32 Mn
Mar 31, 2025 10.56 Mn
Dec 31, 2021 11.14 Mn
Sep 30, 2021 9.99 Mn
Jun 30, 2021 8.88 Mn
Mar 31, 2021 8.82 Mn
Dec 31, 2020 9.07 Mn
Sep 30, 2020 4.53 Mn
Jun 30, 2020 10.36 Mn
Mar 31, 2020 20.87 Mn
Dec 31, 2019 15.14 Mn
Sep 30, 2019 25.52 Mn
Jun 30, 2019 14.74 Mn
Mar 31, 2019 20.66 Mn
Dec 31, 2018 18.72 Mn
Sep 30, 2018 17.92 Mn
Dec 31, 2015 25.49 Mn
Dec 31, 2014 34.63 Mn
Dec 31, 2013 38.93 Mn
Dec 31, 2012 36.80 Mn